1 From City of Hope Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fox Chase Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; The University of Texas MD Anderson Cancer Center; University of Washington/Seattle Cancer Care Alliance; Moffitt Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women’s Cancer Center; Massachusetts General Hospital Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; Memorial Sloan-Kettering Cancer Center; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Stanford Cancer Institute; Huntsman Cancer Institute at the University of Utah; and National Comprehensive Cancer Network.
These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.